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Table 1: Drug Data Summary
Glioma is a deadly brain cancer, and current treatments have been 
unsuccessful in prolonging life more than a few months. In an effort to
discover better treatments with more direct targets, we are conducting a 
chemical screen using Tyrosine Kinase inhibitors (Selleck Biochem). 
Promising results of such inhibitors will suppress the progression of 
glioma by (a) inhibiting the underlying molecular pathways activated in 
glioma, or (b) prevent rapid proliferation of the glia and other cells that 
encompass the glioma tumor. We have induced glioma in Drosophila by 
activating two of the most common oncogenic pathways, PI3K and 
Ras/MAPK. The activation of these pathways results in an enlarged 
brain from an increase in stem cells and their glia and neural progeny. 
These tumors cause the larvae to enter a prolonged larval phase, and 
eventually kill the organism. During our screen, larvae are added to food 
in their early third instar phase (72h old). The food is infused with 10 or 
300uM chemicals in DMSO and where we then see effects on glioma 
growth, and survival in mature third instar stage (120h old). Using these 
metrics, here we present data from our screen on promising drugs from 
this academic year’s testing focusing on drugs E7, E9, and E11. Once 
we identify potential glioma inhibitors in the primary screens, we will 
validate them in secondary screens.
Abstract
Introduction
The goal of this experiment is to determine the limit of growth and 
progression of glioma after being treated with recently approved drugs that 
target Tyrosine kinases. The pathway used for the limit of the growth and 
progression of glioma are the Ras/MAPK and PI3K pathways in the model 
organism, Drosophila Melanogaster. The most frequent oncogenic 
mutation in most tumors, along with glioma is RasV12. When RasV12 is 
activated, the result is cell proliferation and tumor invasions.
The PI3K pathway, a growth regulatory pathway that’s responsive to 
growth factors, is also known to be responsive to many tumor suppressor 
genes apart of the same pathway. Pten is one of those tumor suppressor 
genes and it results in negative regulation of the PI3K pathway. We 
expressed PtenRNAi with activated RasV12 to successfully model glioma in 
fly brains, since Pten mutations are found in patients’ biopsies of glioma.
In this chemical screen, we tested the effectiveness of chemicals, more 
specifically the effectiveness of chemicals E7, E8, E11. The effectiveness 
is examined by dissecting the brain, along with imaging larvae brains and 
checking the survival rates of the larvae. We present our results on the 
inhibitors effect on glioma growth and the evidence for the overall 
effectiveness of this screen on the model organism.
Glioma Progression
Conclusions
• The present drug screen examined potential tumor suppressing 
effects of tyrosine kinase inhibitors from a chemical library tested in a 
Drosophila model of glioma. 
• Through our drug screen, we have tested drugs A-H in the chemical 
library. We have focused the present poster on P1E7, P1E9, and 
P1E11. Through our current results, we found that chemicals P1E7 
and P1E11 both had tumor suppressing effects, at 300 uM and 10 
uM respectively. 
• The chemical P1E9 demonstrated no change in glioma size. 
• Since both P1E7 and P1E11 demonstrated glioma inhibition, we plan 
to further validate these findings by performing secondary screens.
• In the future, we will continue analyzing other drugs from the 
chemical library in order to determine which chemicals are most 
effective in inhibiting glioma growth, as well as their optimal 
concentrations.
Future Directions
1. We plan to continue the chemical screen using additional drugs 
from the Selleck Biochem Chemical library.
2. We will begin to validate the potential glioma reducers to find the 
specificity and efficacy of these potential modifiers of glioma 
growth.
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Control Smaller Larger
Repo>GFP Repo>GFP; Pteni; RasV12
Repo>GFP; 
Pteni; RasV12
Scales Used for Comparison
Overview of Enhancers & 
Suppressors 
10um 300um 
E7 Drugs In Progress. Showed slight Reduction. 
E9 Drugs No visual change 
in glioma size 
In Progress. 
E11 Drugs Showed overall 
suppression
In Progress. 
P1E7 (300um) - Suppression P1E9 (10um) – No Change
P1E11 (10um) – Suppression
